Physiology of Cognition and Alzheimer’s Prevention
Our group's main aim is to understand the biological processes that precede the onset of Alzheimer's disease and its clinical manifestations. This will lead to establishing prevention programmes to halt, or at least delay, the onset of cognitive impairment and, ultimately, dementia, in asymptomatic people at risk of developing the disease. We are a group affiliated with the Barcelonaβeta Brain Research Centre (BBRC), the research centre of the Pasqual Maragall Foundation.
Recent studies have demonstrated that Alzheimer's disease pathology develops over decades before the clinical symptoms appear; this silent, asymptomatic period is known as the pre-clinical phase of Alzheimer's disease. Detecting and understanding this pre-clinical stage generates opportunities for developing new therapeutic strategies. For this reason, it has been hypothesised that, in order to increase the chances of success, drugs that have failed in trials involving symptomatic patients should be tested in cognitively unimpaired individuals who have a high risk of developing the disease.
The Alfa Study is the basis for establishing protocols and research studies, both observational and interventional, for participants at risk of cognitive impairment due to Alzheimer's disease. Alfa participants are invited, according to their characteristics, willingness, and availability, to take part in Alzheimer's prevention studies. In addition to the Alfa study and related sub-studies, we also investigate people with mild symptoms (subjective memory complaints and mild cognitive impairment).
Raffaele Cacciaglia (Researcher)
Noemí Carranza Herrezuelo (Researcher)
Marta Crous Bou (Researcher)
Carles Falcon Falcon (Researcher)
Juan Domingo Gispert López (Researcher)
José María González de Echávarri (Researcher)
Oriol Grau Rivera (Researcher)
Eider Martínez de Arenaza Urquijo (Researcher)
Carolina Minguillón Gil (Researcher)
Grégory Operto (Researcher)
Aleix Sala Vila (Researcher)
Gonzalo Sánchez Benavides (Researcher)
Marc Suárez Calvet (Researcher)
Anna Brugulat Serrat (PhD Student)
Marta Milà Alomà (PhD Student)
Gemma Salvadó Blasco (PhD Student)
Mahnaz Shekari (PhD Student)
Main Publications with IMIM
• Ewers M, Franzmeier N, Suárez M, Morenas-Rodríguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M, Trojanowski JQ, Shaw LM, Weiner MW, Haass C, Alzheimer's Disease Neuroimaging Initiative. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med 2019; 11(507): eaav6221. IF 17.161. Q1.
• Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sánchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, Hodges AK, Zetterberg H. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimers Res Ther 2019; 11: 94. IF 6.142. Q1.
• Brugulat-Serrat, A. Impact of Alzheimer's disease risk factors on white matter hyperintensities and cognition in cognitively unimpaired individuals. Universitat Pompeu Fabra
- Directors: Molinuevo Guix, José Luis; Gispert, JD; Gramunt, N
- Date of defense: 21/06/2019